A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses

@article{Prow2018AVS,
  title={A vaccinia-based single vector construct multi-pathogen vaccine protects against both Zika and chikungunya viruses},
  author={N. Prow and Liang Liu and E. Nakayama and T. Cooper and Kexin Yan and P. Eldi and J. Hazlewood and B. Tang and T. Le and Y. X. Setoh and A. Khromykh and J. Hobson-Peters and K. Diener and P. Howley and J. Hayball and A. Suhrbier},
  journal={Nature Communications},
  year={2018},
  volume={9}
}
Zika and chikungunya viruses have caused major epidemics and are transmitted by Aedes aegypti and/or Aedes albopictus mosquitoes. The “Sementis Copenhagen Vector” (SCV) system is a recently developed vaccinia-based, multiplication-defective, vaccine vector technology that allows manufacture in modified CHO cells. Herein we describe a single-vector construct SCV vaccine that encodes the structural polyprotein cassettes of both Zika and chikungunya viruses from different loci. A single… Expand
The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates
TLDR
Results demonstrate effective induction of immunity in non-human primates by a recombinant SCV vaccine and illustrates the utility of SCV as a multi-disease vaccine platform capable of delivering multiple large immunogens. Expand
The Safe Baculovirus-Based PrM/E DNA Vaccine Protected Fetuses against Zika Virus in A129 Mice
TLDR
Results suggest that AcHERV-ZIKV could be a potential vaccine candidate for human application, and specifically higher gene transfer efficiency in human cells compared to the wild-type baculovirus vector. Expand
Single dose of a replication-defective vaccinia virus expressing Zika virus-like particles is protective in mice
Zika virus (ZIKV), a flavivirus transmitted primarily by infected mosquitos, can cause neurological symptoms such as Guillian–Barré syndrome and microcephaly. We developed several vaccinia virusExpand
The combined vaccination protocol of DNA/MVA expressing Zika virus structural proteins as efficient inducer of T and B cell immune responses
TLDR
An optimized immunization protocol able to induce high levels of ZIKV-specific T-cell responses, as well as neutralizing antibodies, is provided and the combined use of DNA-based vectors and MVA-ZIKV is reinforced as promising prophylactic vaccination schedule against ZikV. Expand
NS1 DNA vaccination protects against Zika infection through T cell–mediated immunity in immunocompetent mice
TLDR
It is demonstrated that vaccine-induced anti-NS1 antibodies fail to confer protection in the absence of a functional T cell response, highlighting the importance of using NS1 as a target for T cell–based ZIKV vaccines. Expand
A Zika Vaccine Generated Using the Chimeric Insect-Specific Binjari Virus Platform Protects against Fetal Brain Infection in Pregnant Mice
TLDR
BinJ/ZIKA-prME emerges as a potential vaccine candidate for the prevention of CSZ and its ability to protect against fetal brain infection is illustrated. Expand
Construction of a recombinant avipoxvirus expressing the env gene of Zika virus as a novel putative preventive vaccine
TLDR
Although BALB/c mice appear to be an adequate model for ZIKV infection, as it mimics the natural mild infection in human beings, inadequate immune suppression seemed to occur by dexamethasone and different immune suppression strategies should be applied before challenge to reveal any protection of the mice. Expand
A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine
TLDR
An adult female IFNAR-/- mouse model of YFV 17D infection and disease is described that recapitulates many features of infection and Disease in humans and is used to evaluate a new YfV vaccine that is based on a recently described chimeric Binjari virus (BinJV) vaccine technology. Expand
The vaccinia-based Sementis Copenhagen Vector COVID-19 vaccine induces broad and durable cellular and humoral immune responses
The ongoing COVID-19 pandemic perpetuated by SARS-CoV-2 variants, has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vacciniaExpand
Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models
TLDR
Human alphavirus isolates and wild-type mice are used to explore whether infection with one virus leads to cross-protection against viremia after challenge with other members of the Semliki Forest virus antigenic complex, and the ability of a recombinant poxvirus-based CHIKV vaccine and a commercially available formalin-fixed whole-virus GETV vaccine to induce cross-protective responses. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 74 REFERENCES
Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology
  • P. Eldi, T. Cooper, +5 authors J. Hayball
  • Biology, Medicine
  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2017
TLDR
An innovative vaccinia virus (VACV)-derived vaccine platform technology termed Sementis Copenhagen Vector (SCV), which was rendered multiplication-defective by targeted deletion of the essential viral assembly gene D13L is described. Expand
A novel strategy to express different antigens from one modified vaccinia Ankara vaccine vector
TLDR
A co-infection model of antigen delivery in vivo, using the MVA-RABV-HBV recombinant, and a murine immunogenicity study was performed, finding no serum antibodies against RABV or HBV could be detected. Expand
Progress toward a Universal H5N1 Vaccine: A Recombinant Modified Vaccinia Virus Ankara-Expressing Trivalent Hemagglutinin Vaccine
TLDR
The present findings revealed that incorporation of carefully selected HA genes from divergent H5N1 strains within a single vector could be an effective approach in developing a vaccine with broad coverage to prevent infection during a pandemic situation. Expand
A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.
TLDR
A single immunisation with this vaccine consistently induced high titres of anti-chikungunya virus antibodies that neutralised both an old Asian isolate and a Réunion Island isolate from the recent epidemic. Expand
Multivalent and Multipathogen Viral Vector Vaccines
TLDR
The need to develop new vaccines for infectious diseases, increase vaccine accessibility, reduce health costs, and simplify overloaded immunization schedules has driven the idea to combine antigens from the same or various pathogens. Expand
Preexisting Vaccinia Virus Immunity Decreases SIV-Specific Cellular Immunity but Does Not Diminish Humoral Immunity and Efficacy of a DNA/MVA Vaccine
TLDR
The results suggest that preexisting vaccinia virus immunity may not limit the potential of recombinant MVA vaccines to elicit humoral immunity and highlight the importance of immunodeficiency virus vaccines achieving early control at the mucosal sites of challenge. Expand
Multiple Immune Factors Are Involved in Controlling Acute and Chronic Chikungunya Virus Infection
TLDR
It is suggested that chronic arthritic disease is a consequence of persistent, replicating and transcriptionally active CHIKV RNA, and several factors are involved in virus control. Expand
Chikungunya Virus Arthritis in Adult Wild-Type Mice
TLDR
A new adult wild-type mouse model of chikungunya virus arthritis is described, which recapitulates the self-limiting arthritis, tenosynovitis, and myositis seen in humans and provides insights into pathogenesis and a simple and convenient system to test potential new interventions. Expand
Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting
TLDR
It is possible to counteract prior viral immunity by priming with a nonviral, DNA vaccine by utilizing heterologous viral vectors for priming and boosting. Expand
Vaccinia Virus Vectors with an Inactivated Gamma Interferon Receptor Homolog Gene (B8R) Are Attenuated In Vivo without a Concomitant Reduction in Immunogenicity
TLDR
It is demonstrated that the deletion of the VV B8R gene leads to enhanced safety without a concomitant reduction in immunogenicity, and Mice and rats vaccinated with the rVVs showed identical humoral responses to both homologous and heterologous genes expressed by VV. Expand
...
1
2
3
4
5
...